Hilleman Laboratories, India, a non-profit joint venture of pharmaceutical major Merck, Sharp & Dohme, the United States, and Wellcome Trust, the United Kingdom, signed a Memorandum of Understanding (MoU) with National Institute of Cholera and Enteric Diseases (NICED), a part of Indian Council of Medical Research’s (ICMR), to develop a new vaccine for diarrhoea caused by Shigella bacteria.
“Hilleman Labs will take the lead in further development of the vaccine candidate for which NICED has already conducted initial research and also be responsible for its regulatory filings and commercialization,” said Davinder Gill, at Hilleman Labs. NICED will provide support in the research studies.
Shigellosis is one of the leading causes of death among children under five years of age, especially in low-income developing countries of Africa and South Asia. Hilleman Labs is also developing four other vaccines for diarrhoeal diseases. Its rotavirus vaccine is in phase-II clinical trials and the company is in discussions with various companies for potential out-licensing or partnerships.
Technology offer
Interested in this technology?
Request further information or explore potential cooperation with the technology provider.
Technology request
Can you help meet this technology need?
Share a relevant technology, expertise or partnership opportunity with APCTT.